Neurocrine Biosciences, Inc.
588 articles about Neurocrine Biosciences, Inc.
-
Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
9/15/2022
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while maintaining control of the underlying psychiatric disorder.
-
Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress
9/15/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapone) capsules on soluble-catechol-O-methyltransferase (S-COMT) enzyme inhibition.
-
Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners
9/12/2022
Parkinson & Movement Disorder Alliance, in partnership with Neurocrine Biosciences, a leading neuroscience-focused biopharmaceutical company committed to meeting the needs of people with complex and debilitating disorders, announced results from the Survey Assessment: Impact of OFF Time on People with Parkinson's Disease and Their Care Partners.
-
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
9/6/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on Tuesday, September 13, 2022 in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.
-
Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.
-
This week, drugs developed by Neurocrine Biosciences, Akebia, Eliem and Athira all failed to meet expectations in clinical trials.
-
Neuro News: Acadia Receives CRL, Sosei and Microglia Advance Schizophrenia Treatment & More
8/5/2022
This week's highlights in neurological diseases include Acadia receiving a CRL for its ADP drug, Sosei and Neurocrine's schizophrenia drug study moving on to Phase II. -
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
8/4/2022
Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2022 and raised net sales guidance for INGREZZA in 2022.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
7/14/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2022 financial results after the Nasdaq market closes on Thursday, August 4, 2022.
-
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
6/13/2022
Neurocrine Biosciences, Inc. announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, which demonstrated substantial reductions in adrenal androgens and androgen precursors.
-
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
6/8/2022
Neurocrine Biosciences, Inc. will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA.
-
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
6/6/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep.
-
Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
6/6/2022
Neurocrine Biosciences, Inc. was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with classic congenital adrenal hyperplasia.
-
Neurocrine Biosciences Announces Repurchase of Convertible Notes - May 25, 2022
5/25/2022
Neurocrine Biosciences, Inc. announced that it has entered into separate, privately negotiated transactions with certain holders of its existing 2.25% Convertible Senior Notes due 2024 to repurchase approximately $179.4 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of approximately $224.0 million, an amount based in part on the trading price of the Company's common stock and accrued and unpaid interest.
-
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
5/23/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA ® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in person May 21-25 in New Orleans and virtually June 7-10 .
-
U.S. Food and Drug Administration(FDA) has granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
-
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
5/12/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation.
-
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
5/4/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2022.
-
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
5/3/2022
Neurocrine Biosciences, Inc. will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time on Tuesday, May 10, 2022 in Las Vegas.
-
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
4/13/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 4, 2022.